EDAP seeks US trials of prostate treatment:
This article was originally published in Clinica
Executive Summary
EDAP TMS has asked the FDA for permission to begin human clinical trials of its new minimally-invasive, ultrasound-based ablation treatment for prostate cancer. The Ablatherm device uses a focused ultrasound beam to destroy well-defined tumours without affecting the surrounding tissue. The device, which is currently being used to treat localised prostate cancer in a multi-centre European study, has already been used to treat over 300 patients with successful results, said the Vaulx-en-Velin, France-based company.